Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ:AGLE) announced significant presentations at two upcoming virtual meetings. At the 49th Child Neurology Society Annual Meeting, the company will showcase their research on the misdiagnosis of Arginase 1 Deficiency (ARG1-D) as Hereditary Spastic Paraplegia, scheduled for October 12-23, 2020. Additionally, Aeglea will present on ACN00177, a novel enzyme therapy for Homocystinuria, at the American Society of Human Genetics Virtual Meeting from October 27-30, 2020. The posters will be available for download on their website.

AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a poster on the misdiagnosis of Arginase 1 Deficiency (ARG1-D) as Hereditary Spastic Paraplegia at the joint 49^th Child Neurology Society Annual Meeting/16^th International Child Neurology Congress (CNS/ICNA). Additionally, the Company will give a poster presentation on the development of ACN00177, a novel engineered human enzyme therapy being investigated for the treatment of Homocystinuria, at the American Society of Human Genetics (ASHG) Virtual Meeting 2020.

CNS/ICNA Presentation Details

• Title: Arginase-1 Deficiency (ARG1-D) Masquerading as Hereditary Spastic Paraplegia: Implications for Diagnostic Testing
• Poster Number: 510
• Date: October 12-23, 2020
• Location: https://icnapedia.org/congress/icnc2020

ASHG Presentation Details

• Title: Development of a Novel Human Engineered Enzyme (ACN00177) for the Treatment of Homocystinuria
• Poster Number: 3151
• Session: 208 – Mendelian Phenotypes
• Date: October 27-30, 2020
• Location: https://www.abstractsonline.com/pp8/#!/9070/presentation/2479 

The posters will be available for download on the Presentations & Events section of the Company's website.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-presentations-on-arginase-1-deficiency-and-homocystinuria-programs-at-two-upcoming-virtual-medical-meetings-301145824.html

SOURCE Aeglea Biotherapuetics, Inc.

FAQ

What is the focus of Aeglea's presentation on Arginase 1 Deficiency?

Aeglea's presentation focuses on the misdiagnosis of Arginase 1 Deficiency as Hereditary Spastic Paraplegia.

When will Aeglea present their findings on ACN00177?

Aeglea will present their findings on ACN00177 at the American Society of Human Genetics Virtual Meeting from October 27-30, 2020.

What is the poster number for the presentation on Arginase 1 Deficiency?

The poster number for the presentation on Arginase 1 Deficiency is 510.

Where can I find Aeglea's presentation materials?

Aeglea's presentation materials will be available for download on their website under the Presentations & Events section.